TerminatedPhase 2

Treatment of West Nile Virus With MGAWN1

Stopped: Early termination due to the inability to enroll (13 of 120 subjects enrolled)

13 participantsStarted 2009-05

Plain-language summary

This study will test a drug called MGAWN1 for the treatment of West Nile infections.

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. Provide written informed consent
✓. Be \>=18 years of age at the time of enrollment
✓. Have West Nile Fever defined as:
✓. temperature \>38°C, headache, AND
✓. positive diagnostic test for WNV Ribonucleic acid or Immunoglobulin M with serum or cerebrospinal fluid (CSF)
✓. Encephalopathy (depressed or altered level of consciousness, lethargy, or personality change lasting 24 hours)
✓. CSF pleocytosis \>=5 cells/mm\^3
✓. Clinical signs of meningeal inflammation, including nuchal rigidity, Kernig or Brudzinski sign, photophobia, or phonophobia

The Number of West Nile Neuroinvasive Disease (WNND) Participants Who Show Improvement in the Modified Rankin Scale (MRS) (>=1 Improvement in Score)

Timeframe: Study Day 2, 7, 14, 28, and 120

The Number of Participants Who Had At Least 1 Treatment-Related Adverse Event

Timeframe: 120 days

NCT IDNCT00927953

SponsorMacroGenics

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2011-02

Results submitted2012-04-10